Author: Editor

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr John Bartlett (Ontario Institute for Cancer Research, Toronto, Canada) discusses his study on the influence of cut points in the proliferation marker, Ki67, for clinical decision making in breast cancer patients, and suggests that Ki67 could be used as a continuous marker in this setting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent advances in neoadjuvant therapy for breast cancer, including the rationale for the use of the surrogate endpoint for survival, pathological complete response (pCR), in neoadjuvant studies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses the opportunities and challenges of developing new agents for breast cancer treatment, including optimising the use of drugs that target genetically defined breast cancer and the integration of these approaches. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the use of electronic medical records as a source of ‘big data’ that could potentially transform healthcare. CancerLinQ is one initiative that is aiming to aggregate and analyse data collected from patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses the clinical relevance of a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Part 1: http://www.oncologytube.com/v/1034706/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma Part 2: http://www.oncologytube.com/v/1034707/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma, including the trial design, efficacy and safety endpoints, and results. Part 1: http://www.oncologytube.com/v/1034706/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma Part 2: http://www.oncologytube.com/v/1034707/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or after resection surgery. In part 1 of 2 videos, Dr. Jason Luke details those risks and benefits.

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses how prospective randomised trials in breast cancer treatment can adapt to the modern healthcare landscape. There is a promising potential for electronic medical records to provide data that is complementary to randomised trials, thereby improving research approaches in cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discuss recent advances in the management of patients with mantle cell lymphoma, including maintenance treatment and the development of personalised medicine. Part 1: http://www.oncologytube.com/v/1034690/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment Part 2: http://www.oncologytube.com/v/1034691/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discuss novel therapies and the future of chemotherapy-based regimens for the management of patients with relapsed or refractory mantle cell lymphoma. Part 1: http://www.oncologytube.com/v/1034690/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment Part 2: http://www.oncologytube.com/v/1034691/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

What should be the protocol for a rising PSA in an undiagnosed patient? Dr. Geo Espinosa of NYU-Langone Medical Center lays out the desired pathway in the context of patient-centric holistic uro-oncology.

Dr Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) provides an overview of immune approaches for the treatment of breast cancer at the 14th St. Gallen International Breast Cancer Conference 2015, including: The prognostic influence of tumour-infiltrating lymphocytes; Ongoing clinical trials of targeted therapies that modulate the immune system the PD-1 inhibitor, pembrolizumab, for triple-negative breast cancer, and the combination of trastuzumab and PD1-inhibitor for HER2-positive breast cancer; Tumour antigen cancer vaccines and ductal carcinoma in situ (DCIS). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses personalised genomic medicine for breast cancer, including the challenges of designing meaningful clinical trials to identify novel and relevant genetic disease biomarkers and the requirement for collaboration by multidisciplinary teams. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Geo Espinosa of NYU-Langone Medical Center explains the concept of Integrative Urology – the union of traditional and complementary standards of care to provide a more holistic, patient-centric modality.

Dr. Lluis Cecchini of the Hospital del Mar in Barcelona talks about the necessity for patients to become more involved in the management of their disease.

The European Board of Urology recently certified the Urology Department of the Hospital del Mar in Barcelona as a urological training center. Dr. Albert Frances explains the program elements.

The European Board of Urology recently certified the Urology Department of the Hospital del Mar in Barcelona as a urological training center.

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Andrew Davies (University of Southampton, Southampton, UK) discusses a phase II/III study comparing the efficacy and safety of lenalidomide versus investigators choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Studies continue to support the clinical relevance of molecularly distinct subtypes of DLBCL. This programme has been supported by sponsorship from Celgene

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigators choice in relapsed or refractory mantle cell lymphoma, including the study design; efficacy and safety endpoints; and conclusions. This programme has been supported by sponsorship from Celgene

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Martin Dreyling (Ludwig-Maximilians University of Munich, Munich, Germany) discusses novel biologic therapies for the management of patients with non-Hodgkin lymphoma, including a phase II/III study of lenalidomide versus investigators choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

http://cancerGRACE.org/ Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses novel therapeutic combinations that are currently being investigated in the clinic to address the unmet need in mantle cell lymphoma treatment. These therapeutic agents include bortezomib, lenalidomide, ibrutinib and rituximab. This programme has been supported by sponsorship from Celgene

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Umberto Vitolo (Città della Salute e della Scienza di Torino, Turin, Italy) discusses novel therapies for mantle cell lymphoma, including biologic approaches with lenalidomide plus rituximab, ibrutinib and ABT-199. This programme has been supported by sponsorship from Celgene

Ted Okon Executive Director of COA conducts an interview with Author Siddhartha Mukherjee, MD and Producer/Director Barak Goodman about the Ken Burns PBS special Cancer:The Emperor of All Maladies. On PBS March 30th, 31st, and April 1st 2015

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses how the increased interaction between basic scientists, clinicians and patients is improving cancer medicine.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses TRAcking Cancer Evolution through therapy (TRACERx), which is a study that defines lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses how we may be able to anticipate tumour evolutionary trajectories for a more proactive approach in clinical practice.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Jonathan Ledermann (University College London, UK) discusses the collaboration between University College London and the Francis Crick Institute that is hoped to increase the interaction between academia and industry.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses the importance of understanding the genetic changes of tumour evolution for the development of more effective management options that are tailored to individual genetic profiles this is termed precision medicine.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Jonathan Ledermann (University College London, UK) discusses recent advances in the management of ovarian cancer, including the use of the poly ADP-ribose polymerase (PARP) inhibitor, olaparib, as maintenance therapy for BRCA-mutated ovarian cancer; anti-angiogenic agents, such as cediranib; and immunomodulatory drugs, such as immune checkpoint inhibitors.

Reports emerging data about molecular subtyping of early-stage breast cancer and patients’ risk of disease recurrence Steven C. Shivers, PhD., Charles E. Cox, MD,

Genomic Profiling, African-American Women and Breast Cancer Risk

Gene Called USP9X and Tamoxifen Resistance

Metastatic Breast Cancer – ER-Positive – Dr. Eitan Amir summarizes the latest updates in ER positive breast cancer from the SABCS meeting in 2014

Biology and Pathology Insights – Dr. John Bartlett presented this session as a summary of the topic from original research presented at the SABCS 2014 session

Dr. John Bartlett Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer

Dr. Eileen Rakovitch A large prospectively-designed study of the DCIS score: Predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation – presented at the officially licensed Best of SABCS meeting in Toronto.

Surgical Oncology Highlights summarized from the San Antonio Breast Cancer Symposium sessions, and presented by Dr. Jean-Francois Boileau as part of the licensed Best of SABCS session in Toronto, in January 2015.

Radiation Oncology Highlights – Dr. Eileen Rakovitch summarizing top results from the San Antonio Breast Cancer Symposium

Advances in Early Breast Cancer (Chemotherapy and Targeted Therapy as well as Endocrine Therapy) are discussed by Dr. Maureen Trudeau from Sunnybrook Cancer Centre, Toronto, Canada

Neoadjuvant Treatment of Breast Cancer – A summary of the San Antonio Breast Cancer Symposium 2014, during the OncologyEducation licensed meeting in Canada, presented by Dr. Susan Dent

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Umberto Vitolo (Città della Salute e della Scienza di Torino, Turin, Italy) discusses recent advances in the management of mantle cell lymphoma, including a maintenance approach for young patients and ibrutinib therapy for relapsed patients.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent studies of the Bruton’s tyrosine kinase inhibitor, ibrutinib, in mantle cell lymphoma (MCL), including in patients with relapsed or refractory MCL who progress after bortezomib therapy and mutational analysis of these patients with primary resistance to ibrutinib, and ibrutinib in combination with rituximab.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses recent investigational advances in chimeric antigen receptor (CAR) T-cell immunotherapy for haematological malignancies, including refractory acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL). The understanding of CLL biology is changing how the disease is managed. Prognostic markers help to identify specific patient subgroups and provide insight disease progression in these groups. New studies in drugs, such as ibrutinib, target cell proliferation.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent advances in the management of mantle cell lymphoma (MCL), including rituximab maintenance after autologous stem cell transplantation in younger patients, bortezomib (Velcade)-based combinations, and lenalidomide as a single agent and in combination with rituximab (R-squared).

A summary of the new uses of immunotherapy and biomarkers in the treatment of NSCLC by Dr. Nayer Rizvi

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL). Balancing treatment efficacy versus toxicity is important and there is reference to the CLL10 study. Anti-CD1 monoclonal antibody therapy after completing chemotherapy, the 17p deletion, allogeneic transplants and a ‘chemo-free’ approach are also considered.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses recent advances in the management of patients with mantle cell lymphoma (MCL). Rituximab maintenance after autologous haematopoietic stem cell transplantation resulted in prolonged progression-free survival. Ibrutinib is being considered for frontline treatment in MCL.